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Abstract
Eribulin plus capecitabine as adjuvant therapy was feasible in postmenopausal women with early-stage,
human epidermal growth factor receptor 2-negative, estrogen receptor-positive breast cancer. The mean
relative dose intensity was 90.6%, and the feasibility rate was 81.3%with the standard dosing schedule for both
drugs. An alternative schedule for capecitabine (7 days on, 7 days off) was better tolerated in a supplemental
group of 10 patients.
Background: The present phase II, open-label, multicenter study explored the feasibility, safety, and tolerability of
eribulin, a novel non-taxane microtubule inhibitor, plus capecitabine as adjuvant therapy. Patients and Methods:
Postmenopausal women with early-stage, human epidermal growth factor receptor 2 (HER2)-negative, estrogen-
receptor (ER)-positive breast cancer received four 21-day cycles of treatment with eribulin mesylate (1.4 mg/m2
intravenously on days 1 and 8 of each cycle) combined with capecitabine (900 mg/m2 orally twice daily on days 1-14 of
each cycle [standard schedule] or 1500 mg orally twice daily using a 7-days on/7-days off schedule [weekly schedule]).
Feasibility was determined by the relative dose intensity (RDI) of the combination using prespeciﬁed criteria for 80% of
patients achieving an RDI of  85%, with a lower 95% conﬁdence boundary > 70%. Results: The mean RDI was
90.6%, and the feasibility rate was 81.3% among women (n ¼ 67, mean age, 61.3 years) receiving the standard
schedule and 95.6% and 100% among women (n ¼ 10, mean age 62.3 years) receiving the weekly schedule. Dose
reductions, missed doses, and withdrawals due to adverse events (most commonly hand-foot syndrome) ascribed to
capecitabine led to a higher RDI (93.5% vs. 87.8%) and feasibility rate (82.8% vs. 71.9%) for eribulin than for
capecitabine using the standard dosing schedule. The most common adverse events were alopecia and fatigue.
Conclusion: Eribulin plus capecitabine with standard or weekly dosing schedules is feasible in patients with early-
stage, HER2-negative, ER-positive breast cancer. Full-dose eribulin (1.4 mg/m2 on days 1 and 8) with capecitabine
(1500 mg orally twice daily, 7 days on/7 days off) is recommended as a regimen for further evaluation.
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Adjuvant Eribulin Plus Capecitabine for Early-Stage Breast Cancerto optimize combination chemotherapy regimens by the addition of
new, promising cytotoxic agents.
Eribulin mesylate is a novel non-taxane microtubule inhibitor
that induces mitotic arrest and apoptosis in cancer cells by mech-
anistically distinct effects on microtubule dynamics that are not
shared by other known anticancer tubulin-targeted agents.2-5 It has
been approved by the US Food and Drug Administration for the
treatment of patients with metastatic breast cancer who have pre-
viously received  2 chemotherapeutic regimens (including an
anthracycline and a taxane in either the adjuvant or metastatic
setting).6 Eribulin has shown efﬁcacy in patients with extensively
pretreated locally advanced or metastatic breast cancer. The objec-
tive response rate in a phase III clinical study was signiﬁcantly
greater for patients treated with eribulin than for those receiving
treatment of physician’s choice (12% vs. 5%; P ¼ .002), accom-
panied by an increase in overall survival (hazard ratio, 0.81; 95%
conﬁdence interval [CI], 0.66-0.99; P ¼ .04).2,7 Eribulin has also
shown a predictable side effect proﬁle, with the most common
adverse events (AEs) associated with treatment generally neu-
tropenia, fatigue, alopecia, nausea, and anemia.2,7,8
The focus of the present study was to explore the feasibility of
adding eribulin to capecitabine as adjuvant therapy in patients with
early-stage, estrogen receptor (ER)-positive breast cancer. Capeci-
tabine was previously studied in the adjuvant setting versus standard
chemotherapy in postmenopausal women > 65 years old and in the
ER-positive subset.9 No difference was seen in the outcomes.9
Eribulin and capecitabine have key toxicities that do not overlap;
thus, theoretically, the eribulin plus capecitabine combination could
improve the probability that the regimen will be well tolerated and
more efﬁcacious. Preliminary safety data from a phase II study of the
combination and efﬁcacy data indicating considerable activity in
metastatic breast cancer patients also provided justiﬁcation for the
initiation of this pilot adjuvant study.10
Patients and Methods
The present study was conducted at 20 centers in The US
Oncology Network after approval of the protocol by the central US
Oncology investigational review board. Each patient voluntarily
provided written informed consent before study participation, and
the patients were free to discontinue at any time. The present study
was conducted in accordance with the principles of the World
Medical Association Declaration of Helsinki, 2008, the Interna-
tional Conference on Harmonization Guideline for Good Clinical
Practice, and applicable national and local laws and regulations.
Patients
Eligible patients included postmenopausal women with histo-
logically conﬁrmed early-stage (stage I-II), HER2-negative, ER-
positive breast cancer. Patients also must have had adequate liver,
renal, and bone marrow function, had an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0 or 1, and
been eligible for adjuvant therapy to begin within 84 days of the
ﬁnal surgical procedure for breast cancer.
The exclusion criteria included stage III and IV invasive breast
cancer; any nonmalignant systemic disease that would preclude the
use of any of the study therapy drugs, including current gastroin-
testinal disease or other conditions resulting in an inability to take orClinical Breast Cancer February 2016absorb oral medications; and pre-existing neuropathy (grade > 2).
Premenopausal women were not eligible because of the absence of
cyclophosphamide, which has ovarian function suppressive effects.
Study Design
The present study was a single-arm, open-label, phase II feasi-
bility study conducted from August 2011 to April 2014. The study
treatment phase included four 21-day cycles of treatment (eribulin
combined with capecitabine). Protocol eligibility was conﬁrmed,
and hematology, clinical chemistry, vital signs, and ECOG PS as-
sessments and physical examinations were conducted within 2
weeks before the start of study treatment. Also, a baseline 12-lead
electrocardiogram (ECG) was performed within 3 days of the ﬁrst
day of the ﬁrst treatment cycle.
Eligible patients were treated with eribulin mesylate 1.4 mg/m2
administered intravenously over 2 to 5 minutes on days 1 and 8 of
each 21-day cycle. Eribulin was given in combination with cape-
citabine, which was administered using 1 of 2 different dosage
regimens. In the ﬁrst regimen, used for most patients (n ¼ 67), 900
mg/m2 capecitabine was administered orally twice daily (a total of
1800 mg/m2) on days 1 through 14 of each 21-day cycle. The
second dosing regimen for capecitabine was initiated after dose re-
ductions and treatment discontinuations were noted and attributed
to capecitabine-related toxicities, including grade 3 or 4 gastroin-
testinal events and hand-foot syndrome, such that the feasibility of
administering  85% of the planned capecitabine dose was 71.9%.
Thus, capecitabine was administered to an additional cohort of 10
patients at a ﬁxed dose of 1500 mg given orally twice daily on a 7-
days on/7-days off schedule continuously during the 4 cycles. This
regimen for capecitabine was based on mathematical modeling11
and has been shown to have an acceptable toxicity proﬁle,
including minimal gastrointestinal toxicity, when given in combi-
nation with bevacizumab to patients with metastatic breast cancer.12
Eribulin was administered at the study site, ensuring compliance
with eribulin dosing. The patients recorded in a daily diary the
number of tablets of capecitabine taken.
Toxicities were managed in individual patients by treatment in-
terruptions and subsequent dose reductions of eribulin or capeci-
tabine, or both. A maximum of 2 dose reductions of either drug was
allowed. Treatment could be delayed in the event of grade 3 or 4
toxicities resulting from either agent. If relationship to a speciﬁc
study drug could be ascertained, the dosage of only that study drug
was modiﬁed.
Warfarin was not permitted because of the likelihood of
drugedrug interactions between capecitabine and warfarin-derived
anticoagulant therapy. Granulocyte colony-stimulating factor (ﬁl-
grastim only) could be used in cycles 2, 3, and 4 if the patient
required a treatment delay of a new cycle owing to an episode of
neutropenia; pegﬁlgrastim was not allowed.
The evaluations included hematology and clinical chemistry as-
sessments, vital signs, and physical examinations, which were per-
formed before study treatment administration on day 1 of each
treatment cycle. The hematology assessments and vital signs were
also performed before treatment on day 8 of each treatment cycle.
An ECG was performed on days 1 and 8 of cycle 1 only (before
dosing and immediately after eribulin administration). AEs and
concomitant medications were assessed throughout the study. The
John W. Smith II et alend-of-treatment visit occurred within 30 days after the last dose of
study medication and included physical examination, recording of
vital signs, ECG, ECOG PS, hematology and clinical chemistry
assessments, and reports of concomitant medications and AEs.
Statistical Analysis
The primary endpoint of the present study was the feasibility of
administering adjuvant eribulin combined with capecitabine for 4
cycles of treatment. Feasibility analyses were conducted on the
evaluable patient data set, which included patients who had met all
inclusion and exclusion criteria, had received  1 dose of eribulin
plus capecitabine, and had completed the study or discontinued
prematurely because of AEs or disease progression. The sample size
of the ﬁrst cohort was based on a minimum of 57 evaluable patients,
which would discriminate between true feasibility rates of  70%
and  85% at a type I error of 5% and power of  85%. The null
hypothesis (H0) was deﬁned as feasibility  70%.
For each patient, the regimen was considered feasible if that
patient was able to achieve a relative dose intensity (RDI) of  85%
of the 4 cycles of eribulin plus capecitabine. The overall RDI for
each patient was calculated as (Dea/Dep þ Dca/Dcp)/2, where Dep
is the planned dose of eribulin (determined by the patient’s body
surface area), Dea is the actual total dose of eribulin administered
during the full 4-cycle regimen, Dcp is the planned dose of cape-
citabine, and Dca is the actual delivered dose of capecitabine during
the full 4-cycle regimen.
The combination regimen was considered feasible and would
warrant further clinical study if  80% of evaluable patients were
able to achieve an RDI of  85%. A 95% CI was constructed using
the exact method. The observed study feasibility rate in the ﬁrst
cohort was also compared to a feasibility rate of 70% using a 1-
sample binomial test. Exploratory feasibility analyses were alsoFigure 1 Distribution of Study Patients aEribulin mesylate 1.4 mg/m
days 1 through 14 on a 21-day cycle. bEribulin mesylate 1
1500 mg twice daily on a 7-days On/7-Days off scheduleperformed for patients who were and were not receiving growth
factors. Descriptive statistics were used to summarize the feasibility
data in the second cohort.
The evaluation of safety (extent of exposure, AEs, clinical labo-
ratory results, vital signs, ECG ﬁndings, ECOG PS, and physical
examination ﬁndings) was performed on the safety analysis set,
which included all patients who had received  1 dose of study
treatment and had undergone  1 post-baseline safety assessment.
The demographic data and other baseline characteristics were
summarized for the safety analysis set, which included all patients
who had received  1 dose of eribulin plus capecitabine, using
descriptive statistics. Analyses of efﬁcacy and safety data were per-
formed separately in each cohort.
Results
Study Patients
A total of 83 patients were screened, and 67 received the standard
dosing schedule (eribulin mesylate 1.4 mg/m2 on days 1 and 8 of
each 21-day cycle plus capecitabine 900 mg/m2 twice daily on days
1-14 of each 21-day cycle). An additional 12 patients were screened,
and 10 were treated with the weekly dosing schedule (eribulin
mesylate 1.4 mg/m2 on days 1 and 8 of each 21-day cycle plus
capecitabine 1500 mg twice daily on a 7-days on/7-days off
schedule throughout the 4 cycles). Most patients not enrolled after
screening were excluded because of failure to meet the inclusion
and/or exclusion criteria (Figure 1). A total of 8 patients (12%) did
not complete the 4 cycles of treatment. Three patients receiving the
standard dosing schedule discontinued (2 withdrew early because of
administrative reasons and 1 withdrew because of anxiety and
depression not related to the study treatment), leaving 64 patients
evaluable for feasibility analyses. An additional 5 patients did not
complete 4 cycles of treatment because of AEs (neutropenia in 22 on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on
.4 mg/m2 on days 1 and 8 on a 21-day cycle plus capecitabine
for 4 cycles
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34 -patients and gastritis, peripheral neuropathy, and muscle weakness
occurring in 1 patient each). One patient receiving the weekly
capecitabine schedule discontinued (for a reason other than pro-
gressive disease, AEs, administrative, or lost to follow-up), leaving 9
patients evaluable for feasibility analyses in this cohort. All enrolled
patients receiving the standard and weekly dosage schedules were
included in the safety analysis sets (Figure 1).
The baseline characteristics of the enrolled patients are listed in
Table 1. All the patients enrolled in the standard dosing schedule were
female, most were white (80.6%), their mean age was 61.3 years, and
most (89.6%) had an ECOG PS of 0. Approximately equal per-
centages had stage I (47.8%) or stage II disease (52.2%), all had ER-
positive disease, andmost (74.6%) had progesterone receptor-positive
breast cancer. The mean interval from breast cancer diagnosis and
surgery to study treatment was 76.3 days and 45.4 days, respectively.
All 10 patients receiving the weekly dosing schedule were female, with
a mean age of 62.3 years, ECOG PS of 0, and stage I (50.0%) and
stage II (50.0%) disease. All had ER-positive disease, and 90.0% had
progesterone receptor-positive breast cancer. The mean interval from
breast cancer diagnosis and surgery to study treatment was 70.6 days
and 47.2 days, respectively.
Feasibility of Eribulin/Capecitabine Combination
Standard Dosing Schedule. A total of 64 patients treated with the
standard dosing schedule were evaluable for the primary endpoint.
The mean  standard deviation (SD) RDI was 90.6%  11.94%Table 1 Patient Demographics and Other Baseline
Characteristics
Characteristic
Eribulin/Capecitabine
Standard Schedulea
(n [ 67)
Weekly Scheduleb
(n [ 10)
Age (years)
Median 62 61
Range 28-80 63-75
Female gender 67 (100) 10 (100)
Race
White 54 (81) 7 (70)
Black or African
American
8 (12) 1 (10)
Native American
or Alaskan Native
1 (2) 0 (0)
Hispanic or Latina 4 (6) 2 (20)
Mean BSA (m2) 1.84  0.207 1.75  0.149
Stage at diagnosis
I 32 (48) 5 (50)
II 35 (52) 5 (50)
ER positive 67 (100) 10 (100)
Progesterone receptor
positive
50 (75) 9 (90)
Data presented as n (%) or mean  standard deviation, unless otherwise noted.
Abbreviations: BSA ¼ body surface area; ER ¼ estrogen receptor.
aEribulin mesylate 1.4 mg/m2 on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on
days 1 through 14 on a 21-day cycle.
bEribulin mesylate 1.4 mg/m2 on days 1 and 8 on a 21-day cycle plus capecitabine 1500 mg
twice daily on a 7-days on/7-days off schedule for 4 cycles.
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limit, 71.4%; P ¼ .030, rejecting H0: feasibility rate  0.7;
Table 2). The RDI and feasibility rates were greater for eribulin
(93.5% and 82.8%, respectively) than for capecitabine (87.8% and
71.9%, respectively). This was because more patients required dose
reductions and had missed doses of capecitabine than eribulin
(Table 2). The AEs considered related to treatment by the inves-
tigator and that had led to dose reductions and drug withdrawals are
listed in Tables 3 and 4, respectively. Most dose reductions were
because of hand-foot syndrome related to capecitabine.
A sensitivity analysis, excluding 9 patients who had undergone
dose reductions in violation of protocol (all had experienced  1
AEs, including grade 1 hand-foot syndrome, elevated aspartate
aminotransferase [AST], elevated alanine aminotransferase, fa-
tigue, mouth infection; grade 2 gastritis, mucositis, elevated
bilirubin, neuropathy, hyponatremia, and acute renal failure; and
grade 3 elevated AST) yielded a feasibility rate of 89.1% (95%
lower CI limit, 79.6%; P ¼ .001, rejecting H0: feasibility rate 
0.7), with an mean  SD RDI of 92.9%  9.8%. In these 55
patients, the RDI and feasibility rates were somewhat greater for
both eribulin (95.1%  10.8% and 87.3%  77.4%, respec-
tively) and capecitabine (90.6%  12.7% and 78.2%  67.1%,
respectively) than in the evaluable patient data set described
above.
The mean  SD RDI for the 12 patients who received ﬁlgrastim
was 85.3%  15.7% and was 91.9%  10.7% for the patients who
did not receive growth factors (n ¼ 52). The corresponding overall
feasibility rates were 66.7% (95% lower CI limit, 39.1%; P > .5,
accepting H0: feasibility rate,  0.7) and 84.6% (95% lower CI
limit, 73.9%; P ¼ .012), with no statistically signiﬁcant difference
between the 2 groups (P ¼ .1510; Pearson c2 test).
Weekly Dosing Schedule. For the 9 evaluable patients who received
the weekly capecitabine dosing schedule, the RDI was 95.6% and
the feasibility rate was 100% (95% lower CI limit, 71.7%). The
RDI and feasibility rates were similar for eribulin (96.6% and
88.9%) and capecitabine (94.6% and 88.9%; Table 2). No patient
receiving the weekly dosing schedule had either drug withdrawn
because of an AE, and none had missed doses of eribulin, although
6 patients (60.0%) had missed doses of capecitabine (Table 2).
Three patients required a reduction in the capecitabine dose because
of hand-foot syndrome, rash, or urticaria, and 1 patient required an
eribulin dose reduction because of neutropenia. The AEs considered
related to treatment and that led to dose reductions are listed in
Table 5. Most dose reductions resulted from hand-foot syndrome
related to capecitabine.
Safety/Tolerability
Safety data were available for all patients. Among the patients
receiving the standard dosing schedule, 14 (20.9%) experienced
treatment-emergent serious AEs (SAEs), with pulmonary embolism
in 3 patients (4.5%) and diarrhea in 2 (3.0%). One patient receiving
the weekly dosing schedule had a treatment-emergent SAE (wors-
ening anxiety). No treatment-related deaths occurred. Twelve pa-
tients (17.9%) required inpatient hospitalization or prolongation of
existing hospitalization because of treatment-emergent treatment-
related AEs. The reasons for hospitalization included febrile
Table 2 Feasibility and Relative Dose Intensity
Parameter Patients (n) Eribulin Plus Capecitabine Eribulin Capecitabine
Standard dosing schedulea
Overall feasibility rate (%) 64 81.3 82.8 71.9
95% CI 71.4-100.0 73.2-100.0 61.2-100.0
P valueb .030 .015 .431
RDI (%) 64 90.6  11.94 93.5  12.10 87.8  15.40
Dose reductions 67 e 14 (21) 24 (36)
Missed doses 67 e 5 (8) 57 (85)
Drug withdrawal for AEs 67 7 (10.4) 1 (1.5) 5 (7.5)
Weekly dosing schedulec
Overall feasibility rate (%) 9 100.0 88.9 88.9
95% CI 71.7-100.0 57.1-99.4 57.1-99.4
RDI (%) 9 95.6  4.91 96.6  7.64 94.6  5.47
Dose reductions 10 NA 1 (10) 3 (30)
Missed doses 10 NA 0 (0) 6 (60)
Drug withdrawal for AEs 10 NA 0 (0) 0 (0)
Data presented as mean  standard deviation or n (%), unless otherwise noted.
A total of 12 patients in the standard dosing schedule group and 1 patient in the weekly dosing schedule group received ﬁlgrastim.
Abbreviations: AEs ¼ adverse events; CI ¼ conﬁdence interval; NA ¼ not applicable; RDI ¼ relative dose intensity.
aEribulin mesylate 1.4 mg/m2 on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on days 1 through 14 on a 21-day cycle.
bObserved study feasibility rate compared with 70% using a 1-sample binomial test.
cEribulin mesylate 1.4 mg/m2 on days 1 and 8 on a 21-day cycle plus capecitabine 1500 mg twice daily on a 7-days on/7-days off schedule for 4 cycles.
John W. Smith II et alneutropenia, pulmonary embolism/deep venous thrombosis,
acute renal failure, and chemotherapy-related gastrointestinal
disorders.Table 3 Eribulin- or Capecitabine-Related Adverse Events Leading
Severityb
Adverse Event All Grades (n [ 67) Grade 2 (n
Hand-foot syndrome 14 (20.9) 5 (7.5
Neutropenia 5 (7.5) 0
Neuropathy, peripheral 5 (7.5) 2 (3.0
ALT increase 4 (6.0) 1 (1.5
AST increase 3 (4.5) 1 (1.5
Fatigue 3 (4.5) 2 (3.0
Diarrhea 2 (3.0) 0
Acute renal failure 1 (1.5) 0
ALP increase 1 (1.5) 1 (1.5
Bilirubin increase 1 (1.5) 1 (1.5
Blister 1 (1.5) 0
Febrile neutropenia 1 (1.5) 0
Gastritis 1 (1.5) 1 (1.5
Hypokalemia 1 (1.5) 0
Hyponatremia 1 (1.5) 1 (1.5
Mucosal inﬂammation 1 (1.5) 0
Nausea 1 (1.5) 1 (1.5
Oral infection 1 (1.5) 0
Stomatitis 1 (1.5) 0
Visual impairment 1 (1.5) 1 (1.5
Data presented as n (%).
Abbreviations: ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate am
aEribulin mesylate 1.4 mg/m2 on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on days 1
bNo grade 5 adverse events developed.All patients receiving the standard dosing schedule and the weekly
schedule experienced treatment-emergent AEs, most commonly al-
opecia (77.6% and 90.0%, respectively), fatigue (58.2% and 60.0%,to Dose Reduction in the Standard Dosing Cohorta Stratiﬁed by
[ 67) Grade 3 (n [ 67) Grade 4 (n [ 67)
) 8 (11.9) 0
2 (3.0) 3 (4.5)
) 3 (4.5) 0
) 0 0
) 2 (3.0) 0
) 1 (1.5) 0
2 (3.0) 0
1 (1.5) 0
) 0 0
) 0 0
0 0
1 (1.5) 0
) 0 0
0 1 (1.5)
) 0 0
1 (1.5) 0
) 0 0
0 0
1 (1.5) 0
) 0 0
inotransferase.
through 14 on a 21-day cycle.
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Table 4 Treatment-Related Adverse Events Leading to Drug Withdrawal in the Standard Dosing Cohorta
Adverse Event Eribulin Only (n [ 67) Capecitabine Only (n [ 67) Eribulin and Capecitabine (n [ 67)
Hand-foot syndrome 0 4 (6.0) 1 (1.5)
Neutropenia 0 0 2 (3.0)
Enteritis 0 0 1 (1.5)
Gastritis 0 0 1 (1.5)
Mucosal inﬂammation 0 1 (1.5) 0
Muscular weakness 1 (1.5) 0 0
Peripheral sensory neuropathy 0 0 1 (1.5)
Pulmonary embolism 0 0 1 (1.5)
Data presented as n (%).
aEribulin mesylate 1.4 mg/m2 on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on days 1 through 14 on a 21-day cycle.
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36 -respectively), and nausea (52.2% and 40.0%, respectively). A total of
24 patients (35.8%) receiving the standard dosing schedule and 2
(20.0%) receiving the weekly dosing schedule experienced neu-
tropenia (grade 3 or 4 in 21 patients [31.3%] in the standard dosing
schedule group and grade 3 in 2 patients [20.0%] in the weekly dosing
schedule group). One half of the patients in both cohorts received
ﬁlgrastim during  1 cycle of therapy, and 50% received ﬁlgrastim
during cycles 2, 3, and 4. Also, 27 patients (40.3%) in the standard
dosing schedule group and 2 (20.0%) in the weekly dosing schedule
group experienced any grade of hand-foot syndrome. One patient
receiving the standard dosing schedule had a prolonged QTc interval
on the end of study ECG that was not present at baseline.
Discussion
The present study was conducted to assess the feasibility of
administering combined eribulin plus capecitabine as adjuvant
therapy in postmenopausal patients with early-stage, ER-positive
breast cancer. Overall, based on the prespeciﬁed criteria that the
combination regimen would be considered feasible if  80% of
evaluable patients were able to achieve an RDI of  85%, the
treatment regimen was deemed feasible. Among the patients who
received the standard dosing schedule (eribulin mesylate 1.4 mg/m2
on days 1 and 8 plus capecitabine 900 mg/m2 twice daily on days 1-
14 on a 21-day cycle), the feasibility rate was 81.3% and the RDI
was 90.6%. A sensitivity analysis conducted of the patients who
underwent treatment dose reductions as recommended per the
protocol had a feasibility rate and RDI that were greater at 89.1%
and 92.9%, respectively. Furthermore, among the patients who
received the weekly dosing schedule (eribulin mesylate 1.4 mg/m2
on days 1 and 8 of each 21-day cycle plus capecitabine 1500 mgTable 5 Eribulin- or Capecitabine-Related Adverse Events Leading
Severityb
Adverse Event All Grades (n [ 10) Grade 2 (n
Hand-foot syndrome 2 (20) 1 (10
Neutropenia 1 (10) 0
Rash 1 (10) 0
Urticaria 1 (10) 0
Data presented as n (%).
aEribulin mesylate 1.4 mg/m2 on days 1 and 8 on a 21-day cycle plus capecitabine 1500 mg twic
bNo grade 5 adverse events developed.
Clinical Breast Cancer February 2016twice daily on a 7-days on/7-days off schedule throughout the 4
cycles), the feasibility rate and RDI were very high at 100% and
95.6%, respectively. These data demonstrate that 4 cycles of eri-
bulin plus capecitabine were generally well tolerated in the adjuvant
setting and would support the conduct of a larger trial to evaluate
the efﬁcacy of this combination.
The combination of eribulin and capecitabine resulted in AEs
that were predictable by their known toxicities. Among the most
common AEs in the present study were alopecia, fatigue, nausea,
neutropenia, and neuropathy, all known side effects of eribulin.2,7,8
The most common capecitabine-related AE was hand-foot syn-
drome. In the present study, most patients were able to achieve and
tolerate the full doses of eribulin and capecitabine for 4 treatment
cycles receiving the standard dosage schedule and the every-other-
week capecitabine schedule. Most dose reductions in the standard
schedule group were due to grade 3 hand-foot syndrome attributed
to capecitabine (11.9% of patients). Grade 3 hand-foot syndrome
has been reported to occur in 8% to 26% of patients receiving
capecitabine monotherapy in phase II and III studies of ﬁrst-line
treatment of metastatic breast cancer.13 Previous studies, for
example, have shown grade 3 hand-foot syndrome occurs in 24% of
patients with advanced breast cancer treated with a combination of
docetaxel and capecitabine14 and in 11% of patients treated with
paclitaxel and capecitabine.15
The addition of eribulin did not appear to potentiate
capecitabine-related hand-foot syndrome or diarrhea, using either
capecitabine dosing schedule. Likewise, capecitabine did not appear
to potentiate eribulin-related neuropathy or neutropenia, which
was managed in the present study by hematopoietic growth
factor support or dose reduction, or both. We recommend theto Dose Reduction in the Weekly Dosing Cohorta Stratiﬁed by
[ 10) Grade 3 (n [ 10) Grade 4 (n [ 10)
) 0 0
1 (10) 0
1 (10) 0
0 0
e daily on a 7-days on/7-days off schedule for 4 cycles.
John W. Smith II et alevery-other-week capecitabine dosing schedule combined with eri-
bulin for further evaluation in the neoadjuvant or adjuvant setting
because fewer patients required dose interruptions and/or dose re-
ductions of eribulin or capecitabine. All patients receiving the
weekly capecitabine schedule achieved an RDI of  85% compared
with 71.9% of patients receiving the standard capecitabine schedule.
Conclusion
The administration of the combination of eribulin plus capecita-
bine is feasible in postmenopausal patients with early-stage, HER2-
negative, ER-positive breast cancer. The addition of eribulin did
not appear to increase the expected incidence of capecitabine-related
hand-foot syndrome nor did capecitabine appear to exacerbate
eribulin-induced neuropathy or neutropenia. Given the effectiveness
of combined eribulin plus capecitabine in metastatic breast cancer
patients and the safety of this combination, eribulin plus capecitabine
is worthy of additional evaluation in the neoadjuvant and/or adjuvant
setting in ER-positive early-stage breast cancer patients.
Clinical Practice Points
 Cumulative and overlapping toxicities can limit the therapeutic
utility of current drug combinations for adjuvant treatment of
ER-positive breast cancer.
 Eribulin and capecitabine have key toxicities that do not overlap;
thus, theoretically, eribulin combined with capecitabine should
improve the probability that the regimen will be well tolerated.
 From our results, eribulin plus capecitabine as adjuvant treat-
ment is feasible in postmenopausal patients with early-stage,
HER2-negative, ER-positive breast cancer.
 The addition of eribulin did not appear to increase the expected
incidence of capecitabine-related hand-foot syndrome nor did
capecitabine appear to exacerbate eribulin-induced neuropathy
or neutropenia.
 The most common AEs observed were alopecia and fatigue.Acknowledgments
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